erythropoiesis-stimulating agent

(redirected from Erythropoiesis stimulating agent)

erythropoiesis-stimulating agent

Abbreviation: ESA.
Any drug that binds to cellular receptors for erythropoietin and encourages red blood cell production by the bone marrow. Members of this class of drugs, which include epoietin and darbopoietin, are used to treat anemia, e.g., in patients with chronic kidney disease, cancer, or aplastic anemia. ESAs are used as an alternative to red blood cell transfusions. Potential side effects of treatment include high blood pressure and an increased risk of blood clots.
See also: agent
References in periodicals archive ?
An erythropoiesis stimulating agent or drug is a medicine which stimulates red blood cells protein erythropoiesis.
Peginesatide: A potential erythropoiesis stimulating agent for the treatment of anemia of chronic renal failure.
Thomas Byrne, was recently recognized as a co-inventor of the underlying technology of Amgen's blockbuster drug Aranesp (darbepoietin alpha), a erythropoiesis stimulating agent (US Patent No.
Tokyo, Japan, Apr 25, 2007 - (JCN) - Kirin Brewery announced that it received manufacturing and marketing approval for its long-acting erythropoiesis stimulating agent Darbepoetin Alfa, brand name NESP(R) Injection Syringe, on April 18, 2007.
Key Words: Anemia, erythropoiesis stimulating agent, chronic kidney disease.
Hematide, a peptide-based erythropoiesis stimulating agent (ESA) being developed by Affymax, is currently in clinical trials for the treatment of anemia associated with chronic kidney disease, cancer and other diseases.
Hematide[TM], a synthetic peptide-based erythropoiesis stimulating agent, maintains hemoglobin in hemodialysis patients previously treated with epoetin alfa (EPO).
If approved, peginesatide will be the first once-monthly erythropoiesis stimulating agent (ESA) available for the treatment of anemia associated with CKD patients on dialysis in the US, the firm said.